← Back
$ACAD All transactions

ACADIA PHARMACEUTICALS INC

▼ SELL 10b5-1 Plan

$ Value

$83K

Shares

3,498

Price

$24

Filed

Sep 16

Insider

Name

Schneyer Mark C.

Title

EVP, CHIEF FINANCIAL OFFICER

CIK

0001899977

Roles

Officer

Transaction Details

Transaction Date

2025-09-15

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

43,447

Footnotes

Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target. | The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Filing Info

Accession No.

0001899977-25-000004

Form Type

4

Issuer CIK

0001070494

Schneyer Mark C.'s History

Date Ticker Type Value
2026-04-07 ACAD $60K
2026-04-05 ACAD M
2026-04-05 ACAD M $0
2026-03-26 ACAD $69K
2026-03-26 ACAD $804
2026-03-25 ACAD $90K
2026-03-25 ACAD M
2026-03-25 ACAD M $0
2026-03-24 ACAD M
2026-03-24 ACAD M $0

Other Insiders at ACAD (90d)

Insider Bought Sold Last
Rhodes Jennifer J
EVP, CHIEF LEGAL OFFICER, SEC
$83K 2026-03-25
Kihara James
PRINCIPAL ACCOUNTING OFFICER
$65K 2026-04-07
Owen Adams Catherine
Chief Executive Officer
$250K 2026-03-25
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
$74K 2026-03-25
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
$219K 2026-04-07